Recombinant IFN-beta Protein, Human (Fc Tag) Recombinant Proteins The human IFNβ (NP_002167.1) (Met 1-Asn 187) was fused with the Fc region of human IgG1 at the C-terminus The recombinant human IFNβ/Fc is a disulfide-linked homodimeric protein. The reduced monomer consists of 404a.a and has a predicted molecular weight of 46.7 kDa. In SDS-PAGE under reducing conditions, the apparent molecular weight of rh IFNβ/Fc monomer is approximately 52 kDa due to glycosylation.
$ $99 In stock
Formulation: The recombinant human IFNβ/Fc is a disulfide-linked homodimeric protein. The reduced monomer consists of 404a.a and has a predicted molecular weight of 46.7 kDa. In SDS-PAGE under reducing conditions, the apparent molecular weight of rh IFNβ/Fc monomer is approximately 52 kDa due to glycosylation.
Source: HEK293 Cells
Usage: Our products are for research use only. This product is not intended or approved for human, diagnostics or veterinary use

Recombinant IFN-beta Protein, Human (Fc Tag)

Formulation: Recombinant IFN-beta Protein was lyophilized from sterile PBS, pH 7.41

Source: HEK293 Cells

Product Name Recombinant IFN-beta Protein, Human (Fc Tag)
Product Type Recombinant Protein
Source HEK293 Cells
Formulation Recombinant IFN-beta Protein was lyophilized from sterile PBS, pH 7.41
Molecular Weight The recombinant human IFNβ/Fc is a disulfide-linked homodimeric protein. The reduced monomer consists of 404a.a and has a predicted molecular weight of 46.7 kDa. In SDS-PAGE under reducing conditions, the apparent molecular weight of rh IFNβ/Fc monomer is approximately 52 kDa due to glycosylation.
Endotoxin < 1.0 EU per μg of the protein as determined by the LAL method
Purity Greater than 95% as determined by SDS-PAGE
Description The human IFNβ (NP_002167.1) (Met 1-Asn 187) was fused with the Fc region of human IgG1 at the C-terminus
Host Species Homo sapiens (Human)
Usage Our products are for research use only. This product is not intended or approved for human, diagnostics or veterinary use
Storage Store recombinant protein under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
AA Sequence Met 1-Asn 187
Product Background Interferons (IFNs) are natural glycoproteins belonging to the cytokine superfamily, and are produced by the cells of the immune system of most vertebrates in response to challenges by foreign agents such as viruses, parasites and tumor cells. Interferon-beta (IFN beta) is an extra-cellular protein mediator of host defense and homeostasis. IFN beta has well-established direct antiviral, antiproliferative and immunomodulatory properties. Recombinant IFN beta is approved for the treatment of relapsing-remitting multiple sclerosis. The recombinant IFN beta protein has the theoretical potential to either treat or cause autoimmune neuromuscular disorders by altering the complicated and delicate balances within the immune system networks. It is the most widely prescribed disease-modifying therapy for multiple sclerosis (MS). Large-scale clinical trials have established the clinical efficacy of IFN beta in reducing relapses and slowing disease progression in relapsing-remitting MS. IFN beta therapy was shown to be comparably beneficial for opticospinal MS (OSMS) and conventional MS in Japanese. IFN beta is effective in reducing relapses in secondary progressive MS and may have a modest effect in slowing disability progression. In addition to the common antiviral activity, IFN beta also induces increased production of the p53 gene product which promotes apoptosis, and thus has therapeutic effect against certain cancers. The role of IFN-beta in bone metabolism could warrant its systematic evaluation as a potential adjunct to therapeutic regimens of osteolytic diseases. Furthermore, IFN beta might play a beneficial role in the development of a chronic progressive CNS inflammation.Immune CheckpointImmunotherapyCancer ImmunotherapyTargeted Therapy
Memo IFB Protein, Human;IFF Protein, Human;IFN-beta Protein, Human;IFNB Protein, Human;Interferon beta Protein, Human
Terminal Met 22
Bioactivity Measured in antiviral assays using WISH human amnion cells infected with vesicular stomatitis virus (VSV). The EC50 for this effect is 0.08-0.8 ng/mL.